Opus Point Partners Management as of Dec. 31, 2017
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 61 positions in its portfolio as reported in the December 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Sage Therapeutics (SAGE) | 10.1 | $12M | 71k | 164.70 | |
| Bristol Myers Squibb (BMY) | 7.2 | $8.3M | 135k | 61.28 | |
| Proshares Tr pshs ult nasb (BIB) | 6.3 | $7.3M | 131k | 56.07 | |
| SPDR S&P Biotech (XBI) | 4.8 | $5.5M | 65k | 84.88 | |
| Nektar Therapeutics (NKTR) | 4.8 | $5.5M | 92k | 59.72 | |
| Alnylam Pharmaceuticals (ALNY) | 4.7 | $5.5M | 43k | 127.04 | |
| Alexion Pharmaceuticals | 4.6 | $5.3M | 45k | 119.59 | |
| Merck & Co (MRK) | 4.1 | $4.7M | 84k | 56.27 | |
| Ignyta | 3.9 | $4.6M | 171k | 26.70 | |
| AstraZeneca (AZN) | 3.6 | $4.2M | 120k | 34.70 | |
| Pfizer (PFE) | 3.5 | $4.1M | 112k | 36.22 | |
| iShares NASDAQ Biotechnology Index (IBB) | 3.5 | $4.0M | 38k | 106.77 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.2 | $2.5M | 17k | 149.89 | |
| Alkermes (ALKS) | 2.1 | $2.4M | 44k | 54.73 | |
| Mettler-Toledo International (MTD) | 1.9 | $2.2M | 3.6k | 619.64 | |
| GlaxoSmithKline | 1.8 | $2.1M | 60k | 35.47 | |
| Illumina (ILMN) | 1.8 | $2.1M | 9.7k | 218.48 | |
| Ionis Pharmaceuticals (IONS) | 1.7 | $2.0M | 39k | 50.29 | |
| Seattle Genetics | 1.6 | $1.9M | 36k | 53.49 | |
| Biogen Idec (BIIB) | 1.6 | $1.8M | 5.8k | 318.49 | |
| Qiagen Nv | 1.5 | $1.7M | 56k | 30.93 | |
| Incyte Corporation (INCY) | 1.5 | $1.7M | 18k | 94.72 | |
| Amgen (AMGN) | 1.5 | $1.7M | 9.9k | 173.92 | |
| Agios Pharmaceuticals (AGIO) | 1.4 | $1.6M | 29k | 57.17 | |
| Regeneron Pharmaceuticals (REGN) | 1.3 | $1.5M | 4.1k | 375.86 | |
| BioMarin Pharmaceutical (BMRN) | 1.3 | $1.5M | 17k | 89.15 | |
| Celgene Corporation | 1.3 | $1.5M | 15k | 104.33 | |
| Eli Lilly & Co. (LLY) | 1.1 | $1.3M | 15k | 84.47 | |
| Loxo Oncology | 1.0 | $1.2M | 14k | 84.20 | |
| Pacira Pharmaceuticals (PCRX) | 1.0 | $1.1M | 25k | 45.64 | |
| Clovis Oncology | 0.9 | $1.0M | 15k | 68.00 | |
| Adamas Pharmaceuticals | 0.9 | $1.0M | 30k | 33.90 | |
| Proqr Thrapeutics N V shs euro (PRQR) | 0.9 | $991k | 308k | 3.22 | |
| Karyopharm Therapeutics (KPTI) | 0.8 | $960k | 100k | 9.60 | |
| Gilead Sciences (GILD) | 0.8 | $936k | 13k | 71.60 | |
| Axsome Therapeutics (AXSM) | 0.7 | $748k | 134k | 5.60 | |
| Paratek Pharmaceuticals | 0.6 | $716k | 40k | 17.90 | |
| Checkpoint Therapeutics | 0.4 | $438k | 113k | 3.88 | |
| Tesaro | 0.4 | $414k | 5.0k | 82.80 | |
| Ultragenyx Pharmaceutical (RARE) | 0.3 | $393k | 8.5k | 46.39 | |
| Medicines Company | 0.3 | $383k | 14k | 27.36 | |
| Bioverativ Inc Com equity | 0.3 | $361k | 6.7k | 53.97 | |
| Neurocrine Biosciences (NBIX) | 0.3 | $326k | 4.2k | 77.55 | |
| Akebia Therapeutics (AKBA) | 0.3 | $312k | 21k | 14.85 | |
| New Senior Inv Grp | 0.3 | $316k | 42k | 7.55 | |
| United Therapeutics Corporation (UTHR) | 0.3 | $303k | 2.1k | 147.80 | |
| Heron Therapeutics (HRTX) | 0.2 | $287k | 16k | 18.08 | |
| Avexis | 0.2 | $277k | 2.5k | 110.80 | |
| Grifols S A Sponsored Adr R (GRFS) | 0.2 | $265k | 12k | 22.91 | |
| Bio-techne Corporation (TECH) | 0.2 | $257k | 2.0k | 129.34 | |
| Juno Therapeutics | 0.2 | $255k | 5.6k | 45.63 | |
| Charles River Laboratories (CRL) | 0.2 | $236k | 2.2k | 109.56 | |
| Recro Pharma (SCTL) | 0.2 | $233k | 25k | 9.23 | |
| Iqvia Holdings (IQV) | 0.2 | $236k | 2.4k | 97.72 | |
| Intercept Pharmaceuticals In | 0.2 | $221k | 3.8k | 58.48 | |
| ACADIA Pharmaceuticals (ACAD) | 0.2 | $207k | 6.9k | 30.09 | |
| Fibrogen (FGEN) | 0.2 | $210k | 4.4k | 47.48 | |
| Intrexon | 0.1 | $164k | 14k | 11.53 | |
| Scynexis | 0.1 | $155k | 67k | 2.33 | |
| Contrafect | 0.1 | $152k | 150k | 1.01 | |
| Progenics Pharmaceuticals | 0.1 | $130k | 22k | 5.97 |
